Nexeon MedSystems is uniquely positioned for success with an extensive portfolio of innovative products that provide minimally invasive solutions to significant clinical needs.

This includes innovative technologies in development such as:

• Proprietary Inversion Point™ stent technology that offers significant improvements over currently available stent systems.
• The prohealing PROTEX Coronary Stent System, which may offer a non-drug solution to the dual problems of restenosis rates of bare metal stents and the late stent thrombosis threat of drug eluting stents. 
• The world’s first balloon-expandable crush-resistant nitinol stent, the CITATION Peripheral Stent System, which can be delivered by a balloon catheter, reducing the number of procedure steps and thereby improving placement accuracy and making deployment easier.

Nexeon also has nanotechnology-based devices, embolic protection systems, local drug/biologic delivery systems and cell delivery/regenerative therapy devices in various stages of development.

CAUTION – Investigational device. Limited by Federal (U.S.) law to investigational use.